Moderna Inc. plans to develop and begin testing vaccines targeting 15 of the world’s most worrisome pathogens by 2025 and will permanently waive the company’s COVID-19 vaccine patents for shots intended for certain low-income and middle-income countries.
Britain said on July 7 the country would provide genomic sequencing support to Brazil, Ethiopia, Kenya, Nigeria and Pakistan to help identify, assess and track new variants of the novel coronavirus.
Novartis AG launched a portfolio of 15 medicines to treat chronic diseases in low- and low-middle-income countries, the drugmaker said in a statement on Thursday. The Basel-based company said […]
